- NSAIDs1 may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS).
- Flurbiprofen tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
FLURBIPROFEN TABLETS USP, 100 mg
Flurbiprofen is a nonsteroidal anti-inflammatory agent.
Flurbiprofen tablets are indicated for the acute or long-term treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
Published Studies Related to Flurbiprofen
Efficacy of the lidocaine/flurbiprofen axetil combination for reducing pain during the injection of propofol. [2011.07]
BACKGROUND: Pain during the injection of propofol is a common clinical problem. Lidocaine pretreatment, preceded by venous occlusion, is the most popular method for reducing pain during the injection of propofol but cannot entirely control such pain. We aimed to evaluate the efficacy of lidocaine, flurbiprofen axetil (an injectable prodrug of flurbiprofen), and the two in combination for reducing pain during the injection of propofol... CONCLUSION: The lidocaine/flurbiprofen axetil combination, compared with lidocaine 40 mg or flurbiprofen 50 mg, effectively reduces pain during the injection of propofol.
Effects of flurbiprofen on CRP, TNF-alpha, IL-6, and postoperative pain of thoracotomy. [2011.03.10]
OBJECTIVE: The aims of this study were to evaluate serum levels of acute phase reactants, such as CRP and cytokines (TNF-alpha and IL-6) in patients who have undergone thoracotomy and to investigate the effects of flurbiprofen on postoperative inflammatory response... CONCLUSIONS: Patients undergoing thoracotomy showed reduced postoperative pain, mean additional analgesic consumption, and serum IL-6 and CRP levels, when flurbiprofen was added to systemic analgesic therapy. Analgesia with anti-inflammatory drug may contribute to the attenuation of the postoperative inflammatory response and prevent postoperative pain in patients undergoing thoracotomy.
Lack of preemptive analgesia by intravenous flurbiprofen in thyroid gland surgery: a randomized, double-blind and placebo-controlled clinical trial. 
BACKGROUND: Nowadays, increasingly more preemptive analgesia studies focus on postoperative pain; however, the impact of preemptive analgesia on perioperative opioid requirement is not well defined. This study was carried out in order to evaluate whether preoperative intravenous flurbiprofen axetil can reduce perioperative opioid consumption and provide postoperative analgesia in patients undergoing thyroid gland surgery... CONCLUSION: Preoperative administration of intravenous Flurbiprofen axetil reduced analgesic consumption during surgery, but not postoperative pain scores.
Efficacy of the lidocaine/flurbiprofen axetil combination for reducing pain
during the injection of propofol. 
pain during the injection of propofol... CONCLUSION: The lidocaine/flurbiprofen axetil combination, compared with
The effect of flurbiprofen as prophylactic analgesic before hysterosalpingography. [2010.09]
Hysterosalpingography (HSG) is associated with pain during the four-step procedure. This prospective, double-blind, randomized, placebo-controlled study was conducted to investigate the effect of the analgesic flurbiprofen, administered prior to HSG, in 60 women...
Clinical Trials Related to Flurbiprofen
A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis [Recruiting]
A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis [Recruiting]
Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction [Completed]
This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug
flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery.
Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis
Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be
eligible for this study.
Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery,
they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and
a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At
the time of surgery, patients will also be given flurbiprofen or a placebo formulation
(look-alike substance with no active ingredient) directly into the extraction site and a
capsule that also may contain flurbiprofen or placebo. One in seven patients will receive
All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for
observation of bleeding and medication side effects. Patients who do not have satisfactory
pain relief from the test medicine after surgery may request a standard pain reliever. A
small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1,
2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total
of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on
the day of surgery will be drawn from the catheter used to administer the sedative; the 24-
and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will
also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after
The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis [Not yet recruiting]
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence [Active, not recruiting]
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of
localized prostate cancer.
PURPOSE: Randomized phase II trial to study the effectiveness of R-flurbiprofen in treating
patients who have localized prostate cancer at risk of recurrence following radiation therapy
Reports of Suspected Flurbiprofen Side Effects
Drug Rash With Eosinophilia and Systemic Symptoms (23),
Renal Failure Acute (5),
Loss of Consciousness (3),
Generalised Erythema (3),
Airway Peak Pressure Increased (3),
Mechanical Ventilation Complication (3),
Dermatitis Bullous (2),
Acute Febrile Neutrophilic Dermatosis (2), more >>
Page last updated: 2013-02-10